01617nam0 22003973i 450 VAN027663720240603121632.489N978303097664420240603d2022 |0itac50 baengCH|||| |||||Niels BohrOn the Constitution of Atoms and MoleculesHelge Kragh editorChamBirkhäuserSpringer2022x, 193 p.ill.24 cm001VAN01034262001 Classic Texts in the Sciences210 BaselBirkhäuserAtomic modelKW:KHistory of physicsKW:KOptical spectraKW:KQuantum TheoryKW:KRadioactivityKW:KCHChamVANL001889KraghHelge S.VANV016989Birkhäuser <editore>VANV108193650Springer <editore>VANV108073650Kragh, Helge StjernholmKragh, Helge S.VANV212776Kragh, H.S.Kragh, Helge S.VANV212778Kragh, H. S.Kragh, Helge S.VANV212777ITSOL20240614RICAhttps://doi.org/10.1007/978-3-030-97664-4E-book – Accesso al full-text attraverso riconoscimento IP di Ateneo, proxy e/o ShibbolethBIBLIOTECA DEL DIPARTIMENTO DI MATEMATICA E FISICAIT-CE0120VAN08NVAN0276637BIBLIOTECA DEL DIPARTIMENTO DI MATEMATICA E FISICA08CONS e-Book 8607 08eMF8607 20240605 Niels Bohr4161003UNICAMPANIA01262nam2 2200289 i 450 MIL012180220251003044224.0883390701519921014d1992 ||||0itac50 baitaitz01i xxxe z01n1TorinoBollati Boringhieri1992XXI, 462 p., \\8! c. di tav.ill.22 cm.001MIL01217562001 ˆ1: ‰Dai tempi primitivi alla caduta degli antichi imperifino al 500 a. C. circa1609TECNOLOGIA. TRATTAMENTO STORICO E GEOGRAFICO19609TECNOLOGIA. STORIA, GEOGRAFIA, PERSONE21ITIT-00000019921014IT-BN0095 IT-SA0112 IT-SA0002 IT-NA0079 IT-NA0261 IT-NA0452 IT-NA0097 NAP BNS.MOD La consegna dei documenti è effettuata dall'Ufficio DistribuzioneMIL0121802Biblioteca Centralizzata di Ateneov. 1.1-4.4 in 8 tomi 01SALA DING 609 STODT 0102 0000015395 VMA A4(0001.1 v. 1.1Y 1994121319941213 01 84 AE BN FT IS SP161339UNISANNIO03483nam 22004935 450 991033750700332120200630065529.03-319-43896-410.1007/978-3-319-43896-2(CKB)4100000007223495(MiAaPQ)EBC5620170(DE-He213)978-3-319-43896-2(PPN)232964114(EXLCZ)99410000000722349520181214d2019 u| 0engurcnu||||||||txtrdacontentcrdamediacrrdacarrierCancer Policy: Pharmaceutical Safety /edited by June M. McKoy, Dennis P. West1st ed. 2019.Cham :Springer International Publishing :Imprint: Springer,2019.1 online resource (129 pages)Cancer Treatment and Research,0927-3042 ;1713-319-43894-8 Pharmacovigilance programs: Do they improve Cancer Drug Safety? -- Impact of Cost on the Safety of Cancer pharmaceuticals -- Assessing pharmaceutical safety in Geriatric Oncology -- Cancer co-Morbidity: Implications for Drug Safety -- Statistical aids to signal generation: Are they effective in Identifying Adverse Cancer Drug Reactions? -- Pharmacovigilance of alternative medications in the Cancer Setting -- Key elements in Adverse Drug Interaction Safety Signals: evaluation of individual case reports in oncology -- Biosimilars: Are they really safe? -- Natural Language processing: improving the identification and communication of Cancer Drug Safety -- The Drug Shortage Crisis in the United States: Impact on cancer pharmaceutical safety -- Anatomy of Risk Evaluation and Mitigation Strategies (REMS) -- Cancer Drug Toxicity: Moving from patient to Survivor.Cancer Policy: Pharmaceutical Safety provides invaluable information on the interesting and compelling field of cancer drug safety. Identifying and understanding high-priority policy issues and key pharmacovigilance strategies is of paramount importance. In this volume, outstanding and original chapters provide an overview and synthesis of the latest thoughts and findings relating to drug safety in the cancer domain. Topics include natural language processing and pharmacovigilance of alternative cancer pharmaceuticals. The information presented in this volume will improve understanding of emerging strategies to identify adverse drug reactions and drug-drug interactions within the cancer setting and will highlight policies that have been instituted to improve cancer patient safety. In summary, Cancer Policy: Pharmaceutical Safety explores many of the important areas of pharmacovigilance research in oncology.Cancer Treatment and Research,0927-3042 ;171OncologyPharmacyOncologyhttps://scigraph.springernature.com/ontologies/product-market-codes/H33160Drug Safety and Pharmacovigilancehttps://scigraph.springernature.com/ontologies/product-market-codes/H69010Oncology.Pharmacy.Oncology.Drug Safety and Pharmacovigilance.615.10289McKoy June Medthttp://id.loc.gov/vocabulary/relators/edtWest Dennis Pedthttp://id.loc.gov/vocabulary/relators/edtBOOK9910337507003321Cancer Policy1736112UNINA